Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
840 stopped studies mapped to Malignant Prostate Neoplasm and descendants · 92% state a reason
Over the 840 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00824928 | Salvage Cryotherapy in Recurrent Prostate Cancer(SCORE) | — | terminated | Jan 19, 2009 | University of Colorado, Denver | Study was ended due to low enrollment | Enrollment / accrual |
| NCT00176293 | Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone… | Phase 2 | terminated | Sep 15, 2005 | University of Kentucky | Slow accrual | Enrollment / accrual |
| NCT02420587 | AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | withdrawn | Apr 20, 2015 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00217464 | Fulvestrant in Treating Patients With Recurrent Prostate Cancer | Phase 2 | terminated | Sep 22, 2005 | Roswell Park Cancer Institute | Closed for futility | Efficacy / futility |
| NCT01274572 | Blood for Immune Response to Provenge® in HRPC | — | withdrawn | Jan 11, 2011 | Mary Crowley Medical Research Center | Drug became available with insurance reimbursement | Other (stated, no rule matched) |
| NCT01267266 | Saracatinib in Treating Patients With Prostate Cancer | Phase 2 | terminated | Dec 28, 2010 | National Cancer Institute (NCI) | Per protocol, study was terminated due to low rate of randomized patients. | Other (stated, no rule matched) |
| NCT00023634 | S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer | Phase 1 | terminated | Jan 27, 2003 | SWOG Cancer Research Network | lack of accrual | Enrollment / accrual |
| NCT00694291 | Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer | Phase 2 | withdrawn | Jun 10, 2008 | Fox Chase Cancer Center | not stated | Not stated |
| NCT01163448 | Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided… | Phase 1 | withdrawn | Jul 15, 2010 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT01565512 | Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort | Phase 1 / Phase 2 | withdrawn | Mar 28, 2012 | Columbia University | Lack of funding, PI left the institution, poor enrollment | Investigator |
| NCT00058214 | Perifosine in Treating Patients With Recurrent Prostate Cancer | Phase 2 | terminated | Apr 9, 2003 | National Cancer Institute (NCI) | Did not meet interim stopping criteria for continuation to the second stage. | Other (stated, no rule matched) |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel… | Phase 1 / Phase 2 | terminated | Oct 5, 2007 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT02159690 | A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and… | Phase 2 | withdrawn | Jun 10, 2014 | Kenneth Pienta, MD | loss of funding | Funding |
| NCT02065323 | A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic… | Phase 2 | withdrawn | Feb 19, 2014 | Oscar Goodman, Jr. | Terminated due to budgetary considerations and length of development. | Funding |
| NCT00429338 | 3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate | N/A | terminated | Jan 31, 2007 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT00824902 | Evaluation Ultrasound Elasticity/Tissue Strain-Hardening Imaging for Prostate Cancer… | N/A | terminated | Jan 19, 2009 | M.D. Anderson Cancer Center | Technical Issues | Other (stated, no rule matched) |
| NCT00511576 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for… | Phase 1 | terminated | Aug 6, 2007 | Mirati Therapeutics Inc. | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All… | Other (stated, no rule matched) |
| NCT01950871 | Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate…(PHSTT-01) | Phase 4 | terminated | Sep 26, 2013 | Advanced Medical Diagnostics s.a. | Sponsor is bankrupt | Other (stated, no rule matched) |
| NCT01838265 | Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without…(MGM) | — | withdrawn | Apr 24, 2013 | University of Miami | Unlikely to Accrue | Enrollment / accrual |
| NCT01469338 | Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer… | Phase 2 | terminated | Nov 10, 2011 | University of Southern California | lack of funding | Funding |
| NCT01531205 | Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | Phase 2 | terminated | Feb 10, 2012 | H. Lee Moffitt Cancer Center and Research Institute | low accrual | Enrollment / accrual |
| NCT00753220 | Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation…(CRITICAL) | Phase 1 / Phase 2 | terminated | Sep 16, 2008 | Bostwick Laboratories | Withdrew the IND with the FDA. | Other (stated, no rule matched) |
| NCT00918385 | Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant…(ARS) | Phase 2 | terminated | Jun 11, 2009 | Duke University | Permanent closure of trial to further accrual based on IDE disapproval | Enrollment / accrual |
| NCT01320787 | 18-F-Fluoroacetate as PET Imaging Agent | Phase 1 | withdrawn | Mar 22, 2011 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | terminated | Nov 25, 2009 | Sandy Srinivas | Decision by funding sponsor due to poor accrual | Enrollment / accrual |
| NCT01704027 | Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for… | Phase 2 | terminated | Oct 11, 2012 | Centre Georges Francois Leclerc | termination of the trial after interim analysis. the main criterion could not be reached | Efficacy / futility |
| NCT00385827 | A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic… | Phase 2 | terminated | Oct 11, 2006 | Centocor, Inc. | Prematurely stopped after Independent Data Monitoring Committee (IDMC) evaluation for lack of… | Efficacy / futility |
| NCT00004050 | Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate… | Phase 2 | terminated | Oct 29, 2003 | Vical | Development in prostate cancer indication halted | Other (stated, no rule matched) |
| NCT00005072 | Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer | Phase 1 / Phase 2 | terminated | Nov 4, 2003 | Vical | Development in prostate cancer indication halted | Other (stated, no rule matched) |
| NCT01688414 | Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer | N/A | withdrawn | Sep 19, 2012 | Stanford University | PI left Stanford | Investigator |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In… | Phase 1 / Phase 2 | withdrawn | Feb 4, 2014 | Emmanuel Antonarakis, MD | This study was never able to open due to lack of funding from the pharmaceutical company. | Funding |
| NCT00949962 | Post-operative or Early Salvage XRT and ADT for High Risk PCa | Phase 3 | terminated | Jul 31, 2009 | European Organisation for Research and Treatment of Cancer - EORTC | Poorly recruiting | Enrollment / accrual |
| NCT00515112 | Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer | Phase 2 | terminated | Aug 13, 2007 | University of Chicago | This study has been terminated due to poor accrual | Enrollment / accrual |
| NCT01483586 | Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer | Phase 2 | terminated | Dec 1, 2011 | KangLaiTe USA | Sponsor decision | Sponsor / business decision |
| NCT00678015 | Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic… | Phase 2 | terminated | May 15, 2008 | University of California, San Francisco | Per protocol - interim analysis showed no significant PSA declines among the first 12 patients… | Efficacy / futility |
| NCT01602783 | 11C Acetate Imaging Post Prostatectomy | N/A | terminated | May 21, 2012 | Massachusetts General Hospital | Slow accrual; no further funding | Enrollment / accrual |
| NCT01100866 | Study of POMELLA™ Extract to Treat Prostate Cancer | N/A | terminated | Apr 9, 2010 | Vancouver Coastal Health | due to slow enrollment | Enrollment / accrual |
| NCT01007214 | Guided Biopsy for Mapping Prostate Cancer(HIT) | N/A | terminated | Nov 3, 2009 | Roswell Park Cancer Institute | Not able to meet accrual | Enrollment / accrual |
| NCT00887640 | Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration… | Phase 2 | terminated | Apr 24, 2009 | Duke University | not stated | Not stated |
| NCT01734681 | Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant… | Phase 2 | withdrawn | Nov 28, 2012 | GenSpera, Inc. | not stated | Not stated |
| NCT01176513 | GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection… | Phase 2 | terminated | Aug 6, 2010 | GE Healthcare | Lack of Subject enrollment | Enrollment / accrual |
| NCT01409473 | Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and…(Prostate SBRT) | Phase 2 | withdrawn | Aug 4, 2011 | Rocky Mountain Cancer Centers | not stated | Not stated |
| NCT00479635 | A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer | Phase 2 | terminated | May 28, 2007 | Cortice Biosciences, Inc. | Sponsor could no longer support; enrollment stopped August 2008. | Enrollment / accrual |
| NCT00922129 | Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in… | Phase 2 / Phase 3 | withdrawn | Jun 17, 2009 | St. Joseph's Healthcare Hamilton | Study did not start up as planned. | Other (stated, no rule matched) |
| NCT01000948 | A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic…(DAPROCA-1) | Phase 2 | terminated | Oct 23, 2009 | Aarhus University Hospital | A consequence of the results of the ENTHUSE phase III study program | Other (stated, no rule matched) |
| NCT00917865 | FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of… | Phase 2 | terminated | Jun 10, 2009 | David M. Schuster, MD | Optimal histolgic verification support such as whole mount analysis could not be made available. | Other (stated, no rule matched) |
| NCT00510224 | Sandostatin for Patients With Androgen Independent Prostate Cancer | Phase 2 | terminated | Aug 1, 2007 | University of California, San Francisco | Stopped at interim analyses phase due to lack of efficacy | Efficacy / futility |
| NCT00681148 | Botulinum Toxin Injection With Prostate Brachytherapy | Phase 2 | withdrawn | May 21, 2008 | Emory University | No funding | Funding |
| NCT00945477 | Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory… | Phase 2 | terminated | Jul 24, 2009 | Illinois CancerCare, P.C. | Slow enrollment | Enrollment / accrual |
| NCT00831233 | Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer | Phase 3 | terminated | Jan 28, 2009 | Ferring Pharmaceuticals | Poor recruitment due to rare targeted population | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 27, 2015source: clinicaltrials